Income Statement (Annual)

HCOM / Hawaiian Telcom Holdco, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Revenue From Contract With Customer Excluding Assessed Tax - - - - - - -
Costs And Expenses
  Cost Of Goods Sold Excluding Depreciation Depletion And Amortization - - - 166,280 162,474 165,835 163,101
  Selling General And Administrative Expense 120,390 108,508 114,875 115,974 123,798 118,420 114,893
  Depreciation Depletion And Amortization 63,806 70,908 77,301 78,014 87,879 89,916 88,424
  Costs And Expenses 344,018 339,642 349,379 360,268 374,151 374,171 366,418
  Operating Income Loss 51,138 45,856 41,771 30,471 19,262 18,792 2,001
Nonoperating Income Expense
  Interest Expense 25,339 22,183 18,875 16,496 16,786 17,095 16,414
  Pension And Other Postretirement Benefit Expense -9,920 - - - - - -
  Nonoperating Income Expense -25,274 -27,236 -22,501 -16,462 -16,805 -17,095 -21,240
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest - - - 14,009 2,457 1,697 -19,239
Income Tax Expense Benefit -1,341 -91,362 8,782 5,910 1,357 591 88,002
Net Income Loss Available To Common Stockholders Basic 26,155 109,982 10,488 8,099 1,100 1,106 -107,241
Earnings Per Share
  Earnings Per Share Basic 0 0 0 0 0 0 -0
  Earnings Per Share Diluted 0 0 0 0 0 0 -0
Weighted Average Number Of Shares Outstanding
  Weighted Average Number Of Shares Outstanding Basic 10,148 10,243 10,337 10,591 10,977 11,503 11,573
  Weighted Average Number Of Diluted Shares Outstanding 10,844 10,661 11,094 11,308 11,386 11,556 11,573

Peers - Communications Services, Not Elsewhere Classified (4899)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 420031106